title: Treatment of nephrogenic diabetes insipidus with prostaglandin synthesis inhibitors.
abstract: The antidiuretic effect of two prostaglandin synthetase inhibitors, ibuprofen (25 mg/kg/day) and indomethacin (2 mg/kg/day), was studied in patients aged 8 to 18 years with hereditary nephrogenic diabetes insipidus. Ibuprofen (studied in five patients) did not have demonstrable effects on urine volume, free water clearance, or osmolar clearance, but fractional excretion of sodium decreased from a mean of 0.38% to 0.19% (P less than 0.05). In contrast, indomethacin (studied in three patients) was associated with a decrease in mean urine volume from 5.8 to 2.8 mL/min and a decrease in mean free water clearance from 3.1 to 1.1 mL/min (both P less than 0.05). Fractional excretion of sodium decreased from 0.77% to 0.27% (P less than 0.01) and was accompanied by an increase in serum urea nitrogen level (P less than 0.01) and a decrease in urea nitrogen clearance (P less than 0.025). Thus, prostaglandin synthetase inhibitors are not uniformly effective in treatment of nephrogenic diabetes insipidus. The inhibitory effect of indomethacin on urine volume and free water clearance in our patients may have been mediated by an enhancement of antidiuretic hormone (ADH)-stimulated cyclic adenosine monophosphate generation, or by increased ADH-independent water reabsorption resulting from an increase in solute reabsorption and consequent medullary hypertonicity.
authors.forename: S
authors.initials: S
authors.lastname: Libber
authors.forename: H
authors.initials: H
authors.lastname: Harrison
authors.forename: D
authors.initials: D
authors.lastname: Spector
mesh_terms: D000293:Adolescent; D001806:Blood Urea Nitrogen; D002648:Child; D002740:Chlorothiazide / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors; D003919:Diabetes Insipidus / Q000188:drug therapy* / Q000235:genetics; D004231:Diuresis / Q000187:drug effects; D004359:Drug Therapy, Combination; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use*; D007213:Indomethacin / Q000627:therapeutic use*; D007671:Kidney Concentrating Ability / Q000187:drug effects; D008297:Male; D009318:Natriuresis / Q000187:drug effects; D009994:Osmolar Concentration; D014556:Urine
chemical_list: D016861:Cyclooxygenase Inhibitors; D002740:Chlorothiazide; D007052:Ibuprofen; D007213:Indomethacin